Literature DB >> 34145876

MOG autoantibodies trigger a tightly-controlled FcR and BTK-driven microglia proliferative response.

Kathryn Pellerin1, Stephen J Rubino1, Jeremy C Burns1, Benjamin A Smith2, Christie-Ann McCarl1, Jing Zhu3, Luke Jandreski3, Patrick Cullen3, Thomas M Carlile3, Angela Li1, Jorge Vera Rebollar1, Jennifer Sybulski3, Taylor L Reynolds3, Baohong Zhang3, Rebecca Basile1, Hao Tang1, Chelsea Parker Harp1, Alex Pellerin1, John Silbereis1, Nathalie Franchimont4, Ellen Cahir-McFarland1, Richard M Ransohoff3, Thomas O Cameron5, Michael Mingueneau1.   

Abstract

Autoantibodies are a hallmark of numerous neurological disorders, including multiple sclerosis, autoimmune encephalitides and neuromyelitis optica. Whilst well understood in peripheral myeloid cells, the pathophysiological significance of autoantibody-induced Fc receptor signalling in microglia remains unknown, in part due to the lack of a robust in vivo model. Moreover, the application of therapeutic antibodies for neurodegenerative disease also highlights the importance of understanding Fc receptor signalling in microglia. Here, we describe a novel in vivo experimental paradigm that allows for selective engagement of Fc receptors within the CNS by peripherally injecting anti-myelin oligodendrocyte glycoprotein (MOG) monoclonal antibodies into normal wild-type mice. MOG antigen-bound immunoglobulins were detected throughout the CNS and triggered a rapid and tightly regulated proliferative response in both brain and spinal cord microglia. This microglial response was abrogated when anti-MOG antibodies were deprived of Fc receptor effector function or injected into Fcγ receptor knockout mice and was associated with the downregulation of Fc receptors in microglia, but not peripheral myeloid cells, establishing that this response was dependent on central Fc receptor engagement. Downstream of the Fc receptors, BTK was a required signalling node for this response, as microglia proliferation was amplified in BtkE41K knock-in mice expressing a constitutively active form of the enzyme and blunted in mice treated with a CNS-penetrant small molecule inhibitor of BTK. Finally, this response was associated with transient and stringently regulated changes in gene expression predominantly related to cellular proliferation, which markedly differed from transcriptional programs typically associated with Fc receptor engagement in peripheral myeloid cells. Together, these results establish a physiologically-meaningful functional response to Fc receptor and BTK signalling in microglia, while providing a novel in vivo tool to further dissect the roles of microglia-specific Fc receptor and BTK-driven responses to both pathogenic and therapeutic antibodies in CNS homeostasis and disease.
© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.

Entities:  

Keywords:  Bruton’s tyrosine kinase; Fc receptor; autoantibody; microglia; myelin oligodendrocyte glycoprotein (MOG)

Mesh:

Substances:

Year:  2021        PMID: 34145876     DOI: 10.1093/brain/awab231

Source DB:  PubMed          Journal:  Brain        ISSN: 0006-8950            Impact factor:   13.501


  6 in total

Review 1.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

2.  Isolation of Microglia and Analysis of Protein Expression by Flow Cytometry: Avoiding the Pitfall of Microglia Background Autofluorescence.

Authors:  Jeremy C Burns; Richard M Ransohoff; Michaël Mingueneau
Journal:  Bio Protoc       Date:  2021-07-20

3.  Differences in Neuropathic Pain and Radiological Features Between AQP4-ON, MOG-ON, and IDON.

Authors:  Hao Kang; Huaiyu Qiu; Xiaofeng Hu; Shihui Wei; Yong Tao
Journal:  Front Pain Res (Lausanne)       Date:  2022-05-09

4.  BTK inhibition limits B-cell-T-cell interaction through modulation of B-cell metabolism: implications for multiple sclerosis therapy.

Authors:  Rui Li; Hao Tang; Jeremy C Burns; Brian T Hopkins; Carole Le Coz; Bo Zhang; Isabella Peixoto de Barcelos; Neil Romberg; Amy C Goldstein; Brenda L Banwell; Eline T Luning Prak; Michael Mingueneau; Amit Bar-Or
Journal:  Acta Neuropathol       Date:  2022-03-18       Impact factor: 15.887

Review 5.  BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies.

Authors:  Aqu Alu; Hong Lei; Xuejiao Han; Yuquan Wei; Xiawei Wei
Journal:  J Hematol Oncol       Date:  2022-10-01       Impact factor: 23.168

Review 6.  Bruton's Tyrosine Kinase Inhibition as an Emerging Therapy in Systemic Autoimmune Disease.

Authors:  Rudi W Hendriks; Odilia B J Corneth; Stefan F H Neys; Jasper Rip
Journal:  Drugs       Date:  2021-10-05       Impact factor: 9.546

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.